Saturday, July 30, 2016 5:50:27 PM
Everything is in my own opinion. Do what you think is right.
Recent LIFE News
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 08:00:00 PM
- aTyr Pharma to Participate in April Investor Conferences • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update • GlobeNewswire Inc. • 03/14/2024 08:00:00 PM
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:20:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:15:45 AM
- aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor • GlobeNewswire Inc. • 01/18/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:35:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:30:22 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/02/2024 05:21:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 11:50:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/21/2023 05:15:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 09:11:52 PM
- aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 10:01:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/09/2023 09:42:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:11:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:06:34 PM
- aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 09:00:00 PM
- aTyr Pharma to Present at November Investor Conferences • GlobeNewswire Inc. • 11/01/2023 12:00:00 PM
- aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 01:01:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 12:04:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM